News
3d
MedPage Today on MSNPulmonary Rehabilitation for COPD Pushes ForwardHome-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but ...
3d
MedPage Today on MSNEasing Airway Assaults in COPDFor COPD patients, the adage holds true: "the first way to get out of a hole is to quit digging one," said Christopher Mosher ...
Last fall, the hospital’s pharmacy team launched an effort aimed at cutting readmission rates for COPD, which are notoriously ...
Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.
6d
Pharmaceutical Technology on MSNSanofi and Regeneron report results from two Phase III trials of COPD treatmentSanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.
Chronic obstructive pulmonary disease (COPD) affects millions of Americans, with new data from the National Center for Health Statistics showing the condition becomes increasingly common as people age ...
Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...
Long-term health care utilization is greater among patients with COPD who have tested positive for COVID-19 and are unvaccinated.
Lung diseases encompass a diverse range of disorders, including Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), ...
The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a Phase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results